Zomedica’s Sales VP Makes Bold Stock Purchase!

Tip Ranks
2025.11.15 02:12
portai
I'm PortAI, I can summarize articles.

Klass Russell Kevin, Zomedica's Senior VP of Sales, purchased 150,000 shares, signaling confidence in the company. Zomedica reported a 16% revenue increase in Q3 2025, driven by strong demand and new revenue streams, but faces profitability challenges with a $6.1 million net loss and delisting risks. Analysts have mixed views, citing revenue growth and strategic initiatives versus weak momentum and valuation issues. The stock is rated Neutral by Spark, TipRanks’ AI Analyst, with a YTD price performance of -32.86% and a market cap of $94.49M.

New insider activity at Zomedica ( (ZOMDF) ) has taken place on November 14, 2025.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Klass Russell Kevin, the Senior Vice President of Sales at Zomedica, has made a significant investment by purchasing 150,000 shares of Zomedica stock. This transaction is valued at $13,500, reflecting a strong vote of confidence in the company’s future prospects.

Recent Updates on ZOMDF stock

Zomedica has reported a 16% increase in revenue for Q3 2025, reaching $8.1 million, driven by strong demand for its therapeutic devices and diagnostic products, as well as the introduction of a new Development Services revenue stream. The company saw a 51% growth in its Diagnostics segment and expanded its international presence through strategic partnerships. Despite these positive developments, Zomedica faces challenges with profitability, as indicated by a net loss of $6.1 million and concerns over delisting risks. Analysts have mixed views on the stock, with some highlighting the company’s revenue growth and strategic initiatives, while others point to weak momentum and valuation issues due to a negative P/E ratio. Zomedica remains focused on product expansion and international growth, with plans to enhance its TRUFORMA platform and launch the TRUVIEW AI platform.

Spark’s Take on ZOMDF Stock

According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.

Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.

To see Spark’s full report on ZOMDF stock, click here.

More about Zomedica

YTD Price Performance: -32.86%

Average Trading Volume: 2,029,774

Technical Sentiment Signal: Hold

Current Market Cap: $94.49M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer